Exhibit 5.1
June 10, 2019
Matter No.:361445
Doc Ref: 15240448
+1441-298-7861
robert.alexander@conyersdill.com
Dermavant Sciences Ltd.
Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB
United Kingdom
Dear Sirs,
Re:Dermavant Sciences Ltd. (the “Company”)
We have acted as special Bermuda legal counsel to the Company in connection with a registration statement onform S-1 as amended (RegistrationNo. 333-231757) initially filed with the U.S. Securities and Exchange Commission (the “Commission”) on May 24, 2019 (the “Registration Statement”, which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to the registration under the U.S. Securities Act of 1933, as amended, (the “Securities Act”) of 7,700,000 common shares of the Company, par value US$0.00001each (the “Common Shares”), together with an additional 1,155,000 Common Shares subject to an over-allotment option to be granted to the underwriters by the Company, all of which are being offered by the Company (all such Common Shares, collectively, the “Shares”).
For the purposes of giving this opinion, we have examined a copy of the Registration Statement. We have also reviewed the memorandum of association and the amended and restatedbye-laws of the Company, each certified by the Secretary of the Company on June 7, 2019, a written resolution of its board of directors dated May 24, 2019 (collectively, the “Resolutions”), an officer’s certificate dated as of the date hereof confirming that the Resolutions were passed at one or more duly convened, constituted and quorate meetings, or by unanimous written resolutions and such other documents and made such enquiries as to questions of law as we have deemed necessary in order to render the opinion set forth below.
Page 1 of 3